CUAMC
JNCE

China Universal Asset Management Company’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

China Universal Asset Management Company’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-484
Closed -$1K – 500
2022
Q3 		$1K Buy
+484
New +$1.71K ﹤0.01% 435

Other funds holding JNCE

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

China Universal Asset Management Company's JNCE Position: Q4 2022 in Review

China Universal Asset Management Company sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2022, closing a stake of 484 shares — an estimated $1K sold.

China Universal Asset Management Company first reported a position in JNCE in Q3 2022 and held it in 1 quarter. The position peaked at $1K in Q3 2022. 85 funds tracked by Wall St. Rank hold JNCE as of Q4 2022.

  • China Universal Asset Management Company reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2022 after selling out during the quarter.
  • China Universal Asset Management Company sold 484 Jounce Therapeutics, Inc. Common Stock shares in Q4 2022, an estimated $1K.
  • China Universal Asset Management Company first reported a position in Jounce Therapeutics, Inc. Common Stock in Q3 2022 and held it in 1 quarter.
  • China Universal Asset Management Company's Jounce Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2022.
  • 85 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2022.

Based on China Universal Asset Management Company's 13F filing for Q4 2022, filed 31 Jan 2023.